Target Name: WDR19
NCBI ID: G57728
Review Report on WDR19 Target / Biomarker Content of Review Report on WDR19 Target / Biomarker
WDR19
Other Name(s): Oseg6 | WD repeat domain 19, transcript variant 1 | Intraflagellar transport 144 homolog | KIAA1638 | ATD5 | CFAP66 | WD repeat-containing protein 19 | WD repeat domain 19 | FAP66 | SPGF72 | intraflagellar transport 144 homolog | WD repeat membrane protein PWDMP | WD repeat-containing protein 19 (isoform 1) | WDR19 variant 1 | WDR19_HUMAN | PWDMP | NPHP13 | ORF26 | IFT144 | CED4 | SRTD5 | DYF-2

Unlocking The Potential of WDR19 as A Drug Target and Biomarker

WDR19 (Oseg6) is a non-coding RNA molecule that has been identified as a potential drug target and biomarker for various diseases, including cancer. Its unique structure and function have made it an attractive target for researchers to study, and its potential as a drug has piqued the interest of pharmaceutical companies.

WDR19 is a RNA molecule that is approximately 200 nucleotides in length. It is expressed in a variety of tissues and cells in the body and is involved in the regulation of gene expression. Studies have shown that WDR19 plays a role in the development and progression of various diseases, including cancer.

One of the key functions of WDR19 is its ability to interact with other molecules in the cell. It has been shown to interact with proteins that are involved in cell signaling pathways, including TGF-β1, NF-kappa-B, and NF-ATP. These interactions suggest that WDR19 may be involved in the regulation of cellular processes that are important for disease development.

WDR19 has also been shown to play a role in the regulation of cell apoptosis, which is the process by which cells die when they have reached their maximum lifespan. Studies have shown that WDR19 can induce cell apoptosis in a variety of cell types, including cancer cells. This suggests that it may be a useful target for drugs that are designed to induce cell death in cancer cells.

Another function of WDR19 is its ability to regulate gene expression. Studies have shown that WDR19 can interact with the protein RNA-binding protein (RBP) and can repress the expression of certain genes. This suggests that WDR19 may be a useful target for drugs that are designed to increase gene expression in certain cells.

In addition to its potential as a drug target, WDR19 has also been shown to be a potential biomarker for various diseases. Studies have shown that levels of WDR19 are elevated in a variety of diseases, including cancer, and that its levels can be used as a diagnostic marker for some of these diseases. This suggests that WDR19 may be a valuable tool for the development of new diagnostic tests for diseases.

Overall, the unique structure and function of WDR19 make it an attractive target for research into its potential as a drug or biomarker. Further studies are needed to fully understand its role in the regulation of cellular processes and its potential as a drug.

Protein Name: WD Repeat Domain 19

Functions: As component of the IFT complex A (IFT-A), a complex required for retrograde ciliary transport and entry into cilia of G protein-coupled receptors (GPCRs), it is involved in cilia function and/or assembly (PubMed:20889716). Essential for functional IFT-A assembly and ciliary entry of GPCRs (PubMed:20889716). Associates with the BBSome complex to mediate ciliary transport (By similarity)

The "WDR19 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about WDR19 comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets

WDR20 | WDR24 | WDR25 | WDR26 | WDR27 | WDR3 | WDR31 | WDR33 | WDR35 | WDR35-DT | WDR36 | WDR37 | WDR38 | WDR4 | WDR41 | WDR43 | WDR44 | WDR45 | WDR45B | WDR46 | WDR47 | WDR48 | WDR49 | WDR5 | WDR53 | WDR54 | WDR55 | WDR59 | WDR5B | WDR6 | WDR62 | WDR64 | WDR7 | WDR70 | WDR72 | WDR73 | WDR74 | WDR75 | WDR76 | WDR77 | WDR81 | WDR82 | WDR82P1 | WDR83 | WDR83OS | WDR86 | WDR86-AS1 | WDR87 | WDR88 | WDR89 | WDR90 | WDR91 | WDR93 | WDR97 | WDSUB1 | WDTC1 | WEE1 | WEE2 | WEE2-AS1 | WFDC1 | WFDC10A | WFDC10B | WFDC11 | WFDC12 | WFDC13 | WFDC2 | WFDC21P | WFDC3 | WFDC5 | WFDC6 | WFDC8 | WFDC9 | WFIKKN1 | WFIKKN2 | WFS1 | WHAMM | WHAMMP1 | WHAMMP2 | WHAMMP3 | WHRN | WIF1 | WIPF1 | WIPF2 | WIPF3 | WIPI1 | WIPI2 | WIZ | WLS | WNK1 | WNK2 | WNK3 | WNK4 | Wnt | WNT1 | WNT10A | WNT10B | WNT11 | WNT16 | WNT2 | WNT2B